Eli Lilly (NY:<a title="Quote for Eli Lilly" href="http://investor.wedbush.com/wedbush/quote?Symbol=NY%3ALLY">LLY )

FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs.

FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included ↗

November 07, 2025

Via Benzinga

Eli Lilly’s Weight-Loss Drug Mounjaro Becomes India’s Top-Selling Medicine By Value: Report ↗

November 07, 2025

The drug has surpassed GlaxoSmithKline’s antibiotic Augmentin, according to a Reuters report on Friday, citing data from research firm Pharmarack.

Topics Government

Trump Announces Deals With Eli Lilly, Novo Nordisk To Lower Obesity Drug Prices ↗

November 06, 2025

Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years? ↗

Topics Government

November 06, 2025

The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗

November 07, 2025

The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.

Via Investor's Business Daily

Topics Government

Eli Lilly Stock Defies Trump’s GLP-1 Pricing Pressure With 6-Day Rally As Wall Street Cheers FDA Boost And New Weight-Loss Drug Data ↗

November 06, 2025

Bank of America Securities called Lilly’s GLP-1 pricing deal “probably a good tradeoff overall,” keeping a ‘Buy’ rating and $950 target.

Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced ↗

Topics Government World Trade

November 06, 2025

Citi calls Trump’s GLP-1 pricing deal “less bad than feared,” while Needham warns it could erode Hims’ cost advantage.

Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound and Wegovy by 2026.

Topics Government World Trade

Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts ↗

November 06, 2025

Via Benzinga

Topics Government

Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx ↗

November 06, 2025

The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026.

Via Benzinga

Topics Government

Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know. ↗

November 06, 2025

Is the fourth time the charm for this Danish pharmaceutical giant?

The Trump administration announced deals Thursday with Eli Lilly and Novo Nordisk to slash the prices of their obesity drugs.

Topics Earnings

Trump Slashes Weight-Loss Drug Prices By Up To 74% In Deal With Lilly, Novo ↗

November 06, 2025

Via Investor's Business Daily

Topics Government

Navigating the Volatility: Q3 2025 Earnings Season Delivers Both Cheers and Concerns

November 06, 2025

The third-quarter 2025 earnings season, largely drawing to a close in early November, has proven to be a dynamic and often surprising period for investors. While a significant majority of S&P 500...

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Topics Artificial Intelligence Economy Stocks

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

Whether you're looking for AI stocks or dividend stocks, there is something for everyone in this list.

Topics Intellectual Property

My 6 Top-Ranked Stocks to Buy Right Now in November ↗

November 06, 2025

Trump Administration's Weight-Loss Drug Deal Is Sending This Novo Nordisk Rival Surging: Momentum Score Spikes ↗

Topics Artificial Intelligence

November 06, 2025

A leading pharmaceutical stock that goes head-to-head against Novo Nordisk A/S is surging amid a potential deal with the Trump administration.

Via Benzinga

Topics Government

Dow Jumps Over 200 Points: Investor Sentiment Improves, Fear & Greed Index Remains In 'Extreme Fear' Zone ↗

November 06, 2025

The CNN Fear & Greed Index eased, but remained in Extreme Fear zone on Wed. Stocks rose on solid earnings & speculation of Fed rate cut.

Via Benzinga

Topics Economy Stocks

1 Mid-Cap Stock for Long-Term Investors and 2 We Question

November 05, 2025

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

Via StockStory

ANI Pharmaceuticals (ANIP) To Report Earnings Tomorrow: Here Is What To Expect

November 05, 2025

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting results this Friday before the bell. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

2 Reasons I'm Keeping My Eye on Eli Lilly Stock Right Now ↗

November 05, 2025

Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

Microsoft Gets $135 Billion OpenAI Stake ↗

November 05, 2025

The Resilient Market: Investor Optimism and the Enduring Power of "Dip-Buying" in November 2025

November 05, 2025

As November 2025 unfolds, the financial markets are characterized by a palpable sense of cautious optimism, a sentiment largely underpinned by the continued prevalence and success of "dip-buying"...

In the intricate tapestry of global financial markets, few metrics hold as much sway and immediate relevance as market capitalization. Representing the total dollar value of a company's outstanding...

Topics Artificial Intelligence ETFs Economy

The Shifting Sands of Valuation: Understanding Market Cap Movers in a Dynamic Market

November 05, 2025

Tech Titans and Pharma Powerhouses Drive Market Volatility: AMD, Palantir, Micron, and Eli Lilly in Focus

Topics Artificial Intelligence Bankruptcy Earnings

November 05, 2025

As of November 5, 2025, the financial markets experienced a day of notable activity, with several key players across the technology and pharmaceutical sectors capturing investor attention. Advanced...

The burgeoning market for obesity and diabetes treatments, particularly GLP-1 receptor agonists, is witnessing a dramatic divergence in fortunes among its leading players. As of November 5, 2025, Novo...

Topics Artificial Intelligence Economy

Obesity Drugmakers Face Shifting Tides: Novo Nordisk Plunges While Eli Lilly Soars

November 05, 2025

Market Recovers from Tariff Turmoil: Dow, S&P 500, and Nasdaq Stage Resilient Rebound Amid Shifting Economic Winds

Topics Economy

November 05, 2025

The U.S. financial markets have demonstrated remarkable resilience in 2025, staging a significant rebound after experiencing a sharp selloff earlier in the year. The Dow Jones Industrial Average, S&P...

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing...

Topics Artificial Intelligence Economy Government

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗

November 05, 2025

Via Benzinga

Topics Economy

AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns

November 05, 2025

Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design...

Via TokenRing AI

Topics Artificial Intelligence Intellectual Property

Market Movers: Eli Lilly, Cadre, BP, Kellanova, and Teva Soar to 52-Week Highs Amidst Shifting Economic Tides

November 05, 2025

In a period marked by cautious optimism and strategic pivots, several prominent companies across diverse sectors have recently defied broader economic uncertainties to achieve significant 52-week...